Teva reports Q3 EPS 78c, consensus 67c

Reports Q3 revenue $4.5B, consensus $4.33B. Richard Francis, Teva‘s (TEVA) President and CEO, said, “Our innovative portfolio driving the 11th consecutive quarter of growth in the third quarter reflects the accelerating momentum of our transformation and the strength of our innovation-led Pivot to Growth strategy. Our key growth drivers-particularly our innovative medicines-delivered a 33% increase in local currency, underscoring their impact on both patient outcomes and our financial performance. As we continue executing our strategy, we remain firmly on track to reach our 30% non-GAAP operating profit margin by 2027 and ~$700 million of net savings target.”